Amyloidosis: A model of misfolded protein disorder;Les amyloses, un modèle de maladie du repliement des protéines

Medecine/Sciences

Volumn 21, Issue 6-7, 2005, Pages 627-633

  Grateau, Gilles ^a   Verine, Jérôme ^b   Delpech, Marc ^c   Ries, Madeleine ^d  

^a HÔPITAL TENON   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; SERUM AMYLOID P;

AMYLOIDOSIS; CLINICAL FEATURE; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STABILITY; REVIEW; STORAGE DISEASE;

EID: 22144475152     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2005216-7627     Document Type: Review

References (35)

1. Grateau G, Benson MD, Delpech M. Les amyloses. Paris: Flammarion Médecine-Sciences, 2000: 580 p.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909.
3. Grateau G. Amyloses. In: Kahn MF, Peltier O, Meyer O, Piette JC, eds. Les maladies systémiques. Paris: Flammarion Médecine-Sciences, 2000: 1279-308.
4. Carter DB, Chou KC. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol Aging 1998; 19: 37-40.
5. Kaplan B, Shtrasburg S, Pras M. Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003; 56: 86-90.
6. Baltz ML, Caspi D, Evans DJ, et al. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66: 691-700.
7. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11: 649-55.
8. Sipe JD, Ed. Amyloid proteins: the beta sheet conformation and disease. Weinheim: Wiley-VCH, 2005 (sous presse).
9. Canet D, Sunde M, Last AM, et al. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 1999; 38 : 6419-27.
10. Hamilton JA, Benson MD. Transthyretin: A review from a structural perspective. Cell Mol Life Sci 2001; 58 : 1-31.
11. Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA 1974; 71: 4864-8.
12. O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279: 17490-9.
13. Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004; 43: 7365-81.
14. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27: 527-33.
15. Niraula TN, Konno T, Li H, et al. Pressure-dissociable reversible assembly of intrinsically denatured lysozyme is a precursor for amyloid fibrils. Proc NatlAcad SciUSA 2004; 101: 4089-93.
16. Korenaga T, Fu X, Xing Y, et al. Tissue distribution, biochemical properties, and transmission of mouse Type A AApoAII amyloid fibrils. Am J Pathol 2004; 164: 1597-606.
17. Lundmark K, Westermark GT, Nystrom S, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 2002; 99: 6979-84.
18. Mudher A, Lovestone S. Alzheimer's disease: do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-6.
19. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 2004; 1019: 1-4.
20. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
21. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279: 46363-6.
22. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94: 1008-10.
23. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
24. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17: 615-20.
25. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004; 47: 355-74.
26. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002; 9: 24-30.
27. Cardoso I, Merlini G, Saraiva MJ. 4′-iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J 2003; 17: 803-9.
28. Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355: 192-7.
29. Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306: 865-9.
30. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143-8.
31. Kisilevsky R, Szarek WA, Ancsin JB, et al. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 2004; 164: 2127-37.
32. Pepys MB, Herbert J, Hutchinson WL. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-9.
33. Dumoulin M, Dobson CM. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 2004; 86: 589-600.
34. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002; 99: 1485-90.
35. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000; 157: 1239-46.